124 related articles for article (PubMed ID: 15235124)
1. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells.
Hölig P; Bach M; Völkel T; Nahde T; Hoffmann S; Müller R; Kontermann RE
Protein Eng Des Sel; 2004 May; 17(5):433-41. PubMed ID: 15235124
[TBL] [Abstract][Full Text] [Related]
2. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin.
Schiffelers RM; Koning GA; ten Hagen TL; Fens MH; Schraa AJ; Janssen AP; Kok RJ; Molema G; Storm G
J Control Release; 2003 Aug; 91(1-2):115-22. PubMed ID: 12932643
[TBL] [Abstract][Full Text] [Related]
4. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins.
Koivunen E; Wang B; Ruoslahti E
Biotechnology (N Y); 1995 Mar; 13(3):265-70. PubMed ID: 9634769
[TBL] [Abstract][Full Text] [Related]
5. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins.
Pasqualini R; Koivunen E; Ruoslahti E
J Cell Biol; 1995 Sep; 130(5):1189-96. PubMed ID: 7657703
[TBL] [Abstract][Full Text] [Related]
6. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
7. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
[TBL] [Abstract][Full Text] [Related]
8. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
Amin M; Badiee A; Jaafari MR
Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
[TBL] [Abstract][Full Text] [Related]
9. A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy.
Murase Y; Asai T; Katanasaka Y; Sugiyama T; Shimizu K; Maeda N; Oku N
Cancer Lett; 2010 Jan; 287(2):165-71. PubMed ID: 19616372
[TBL] [Abstract][Full Text] [Related]
10. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
[TBL] [Abstract][Full Text] [Related]
11. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker.
Gray BP; Li S; Brown KC
Bioconjug Chem; 2013 Jan; 24(1):85-96. PubMed ID: 23186007
[TBL] [Abstract][Full Text] [Related]
12. Definition of an unexpected ligand recognition motif for alphav beta6 integrin.
Kraft S; Diefenbach B; Mehta R; Jonczyk A; Luckenbach GA; Goodman SL
J Biol Chem; 1999 Jan; 274(4):1979-85. PubMed ID: 9890954
[TBL] [Abstract][Full Text] [Related]
13. Development of High-Functionality and -Quality Lipids with RGD Peptide Ligands: Application for PEGylated Liposomes and Analysis of Intratumoral Distribution in a Murine Colon Cancer Model.
Suga T; Kato N; Hagimori M; Fuchigami Y; Kuroda N; Kodama Y; Sasaki H; Kawakami S
Mol Pharm; 2018 Oct; 15(10):4481-4490. PubMed ID: 30179010
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells.
Cressman S; Dobson I; Lee JB; Tam YY; Cullis PR
Bioconjug Chem; 2009 Jul; 20(7):1404-11. PubMed ID: 19534457
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic vessel-targeting DDS by liposomalized oligopeptides.
Asai T; Oku N
Methods Mol Biol; 2010; 605():335-47. PubMed ID: 20072892
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
18. Peptide-mediated gene transfer of cationic lipid/plasmid DNA complexes to endothelial cells.
Anwer K; Kao G; Rolland A; Driessen WH; Sullivan SM
J Drug Target; 2004 May; 12(4):215-21. PubMed ID: 15506170
[TBL] [Abstract][Full Text] [Related]
19. Identification of oligopeptides binding to peritoneal tumors of gastric cancer.
Akita N; Maruta F; Seymour LW; Kerr DJ; Parker AL; Asai T; Oku N; Nakayama J; Miyagawa S
Cancer Sci; 2006 Oct; 97(10):1075-81. PubMed ID: 16984380
[TBL] [Abstract][Full Text] [Related]
20. Integrin Targeting and Toxicological Assessment of Peptide-Conjugated Liposome Delivery Systems to Activated Endothelial Cells.
Kermanizadeh A; Villadsen K; Østrem RG; Jensen KJ; Møller P; Loft S
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):380-389. PubMed ID: 27767251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
